First in Human Study of M6223

NCT04457778 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Solid Tumors

Interventions

DRUG: M6223
DRUG: Bintrafusp alfa
DRUG: M6223

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

[object Object]